Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A new study from Montefiore Einstein Cancer Center found that CAR-T therapy was effective in Black and Hispanic patients, with outcomes comparable to those of white and Asian patients. The study showed no statistical differences in clinical outcomes or side effects among racial and ethnic backgrounds.
The composition of microorganisms living in the gut influences response to conventional cancer treatments and novel immunotherapies. Recent studies suggest that targeting the gut microbiome could diminish side effects of chemotherapy, while diet, probiotics, and antibiotic medications may also impact clinical responses.
Cancer cells employ a unique defense mechanism to evade the effects of radiation treatment by exploiting an enzyme called Caspase-activated DNase (CAD). Removing CAD from cancer cells increases the effectiveness of radiotherapy. Researchers hope their discovery can lead to the development of targeted drugs to enhance cancer treatment.
Researchers from Columbia University have developed a plug-and-play multi-organ chip, customized to the patient, consisting of engineered human heart, bone, liver, and skin linked by vascular flow. The model allows for long-term studies and can be optimized for personalized therapy optimization in cancer and systemic diseases.
The University at Buffalo is developing new treatments for ovarian cancer by targeting the apelin receptor. Ovarian cancer cells rely on lipids for energy and survival, making this a promising therapeutic target.
Researchers at Texas A&M University developed a low-cost, minimally invasive wireless device that uses photodynamic therapy to kill cancer cells. The device enables precise and safe treatment options during surgery, potentially reducing the need for additional treatments like chemotherapy.
Researchers from IRB Barcelona and Merus have discovered MCLA-158, a bi-specific antibody targeting cancer stem cells. The treatment prevents metastasis and slows primary tumor growth in experimental models of cancer.
Deleting or inhibiting a protein called lysine-specific demethylase 1 (LSD1) may curb the growth of oral squamous cell carcinoma tumors. The study found that disrupting LSD1 promotes anti-tumor immunity, which can help fight cancer. The discovery could lead to new and potentially more effective therapies for oral cancer patients.
A study by Brigham and Women's Hospital found that more than half of cancer centers do not publicly disclose payer-specific prices for patients with private health insurance. The study also revealed significant markups in drug prices, ranging from 120% to 630% above the hospital cost.
Research from Weill Cornell Medicine found that less prostate cancer screening has reduced overdiagnosis, but increased incidence of high-grade and metastatic disease. The study analyzed over 438,000 men with newly diagnosed prostate cancer between 2010 and 2018.
A study published in Cancer Medicine suggests that exosomes produced by adipose-derived mesenchymal stem cells can effectively deliver RNA-based anti-cancer treatments to bladder cancer tumors. This novel approach shows promise as a potential therapeutic agent for bladder cancer treatment, offering new hope for patients.
The ESMO Breast Cancer Congress 2022 event will present more than 200 studies on various aspects of breast cancer, including new treatments and innovative clinical practices. The congress will be held onsite in Berlin, Germany, and online, offering a platform for breast cancer specialists to share knowledge and improve patient outcomes.
Researchers at the University of Oklahoma are testing a novel therapy that combines local laser ablation and immunostimulants to treat metastatic pancreatic cancer. The treatment aims to stimulate the immune system to fight cancer cells, with promising preliminary results in pre-clinical studies and clinical trials.
Researchers at Aarhus University have developed improved DNA nanostructures that can assemble biomolecules with multiple functions, increasing the effectiveness of cancer treatment. The new structures are more stable, non-toxic, and immune system-friendly than previous versions.
Researchers are developing radioconjugate drugs that combine radiation with a tumor-targeting agent to selectively kill cancer cells. Two approved drugs, Lutathera and Pluvicto, demonstrate the potential of this therapy, which could change the future of cancer treatment.
A new study reveals a gene called KLF4 that normally suppresses tumor formation but is reprogrammed in acute promyelocytic leukemia, an aggressive type of blood cancer. Overexpressing KLF4 can suppress the growth of cancerous cells and reverse the effects of the disease.
Researchers at Charité - Universitätsmedizin Berlin have discovered a novel mechanism that restricts cell division in healthy stomach tissue, protecting against cancerous changes. However, Helicobacter pylori infection deactivates this mechanism, enabling cells to grow uncontrollably and increasing the risk of stomach cancer.
Researchers at the Lewis Katz School of Medicine defined 11 subsets of cells found in esophageal tissue using single cell gene-expression profiling. This study could help clinicians diagnose or treat certain types of cancer by identifying functional cell types contributing to cancer progression.
Researchers have shed light on how immune checkpoint protein LAG3 modulates T cell activity, providing crucial information for the development of new LAG3-blocking therapies. The study found that LAG3 suppresses T cell activation by disrupting coreceptor-Lck association, even in the absence of MHC Class II molecules.
Researchers load CAR-T cells with an oncolytic virus to target and kill solid cancer tumors, providing a potent immune response. The combination approach overcomes challenges in treating solid tumors with CAR-T cell therapy alone.
The TTUHSC's C. Patrick Reynolds has received a $1.34 million CPRIT grant to investigate updating the clinical risk stratification scale for neuroblastoma and rhabdomyosarcoma, two childhood cancers in need of improved therapies.
A phase two randomised placebo controlled trial showed giving patients nintedanib, as well as chemotherapy before surgery or radiotherapy, significantly increased overall survival rates at one, two and five years. Nintedanib blocks different proteins from sending signals to cancer cells to grow, causing the cancer cells to die.
Researchers identified clofarabine as a promising compound with inhibitory effects on bladder cancer cells, including urothelial carcinoma and sarcomatoid carcinoma. The study suggests potential for clinical trials to treat metastatic bladder cancer patients who cannot receive traditional cisplatin-based therapy.
Researchers at UC San Diego found that ovarian cancer tumors activate FAK protein to regulate CD155 expression, creating a shield against immune detection and evading treatment. New molecular targets may boost immune response and lead to new combinatorial strategies for this disease.
The RACE Act has led to an increase in required studies for cancer drugs targeting molecular targets relevant to pediatric cancer. Since its implementation, 42.9% of approved drugs have been required to conduct pediatric studies, up from 8.3% before the act.
Adding immunotherapy to chemotherapy before surgery reduced the risk of recurrence and death in lung cancer patients by 37%, according to a phase III trial. The treatment also led to a nearly twelvefold increase in pathological complete response, with 24% of patients achieving no active cancer remaining when the tumor was removed.
Researchers developed an AI model to predict side effects from new combination therapies by analyzing over 15 million records of adverse events. The model can recognize patterns between drugs and their side effects, enabling the prediction of adverse events for individual therapy profiles.
Researchers at CU Cancer Center have developed a lead drug that inhibits the oncogene CHD1L, a chromatin remodeling enzyme that aids tumor progression and metastasis in many cancer types. The drug, called 6.11, has shown promising biological activity against CHD1L.
Recent studies published in the Journal of Pharmaceutical Analysis have found applications of nanotechnology in medicine, drug research, and environmental protection. Researchers developed nanodots made of carbon using natural polysaccharides from mushrooms to detect chromium, and created nanozymes that could be used to detect drug con...
Scientists at the University of Bath have developed a new technique called Transcription Block Survival (TBS) to accelerate the discovery of cancer-fighting drugs. TBS identifies molecules that can shut down dangerous proteins before they wreak havoc, by blocking their interaction with cell DNA.
Researchers at MUSC have developed a device to remove toxic chemotherapy drugs, such as doxorubicin, from the blood after cancer treatment. The device uses heat and an activated carbon filter to effectively remove the drug, potentially reducing harmful side effects.
A new biodegradable gel has been developed to improve the immune system's ability to combat cancer. The gel releases drugs and special antibodies that target tumor cells, slowing their growth and increasing the lifespan of mice. This breakthrough could lead to new clinical trials for human patients in the coming years.
Researchers have identified a process to study circulating tumor cells responsible for cancer recurrence in patients with non-small cell lung cancer. The study models showed that these cells correlated with cancer recurrence, and blocking a protein called MYC made the tumor cells more vulnerable to chemotherapy.
Researchers have developed a method to chart the first-ever map of allosteric sites in two common human proteins, revealing they are abundant and identifiable. This could lead to safer, smarter, and more effective medicines by targeting these 'secret doors'.
A study found that childhood cancer survivors who received combined chemotherapy and radiotherapy have a higher risk of dental developmental anomalies. The first signs of dental disturbances can appear within one or two years after treatment. Researchers identified specific treatments and age factors associated with increased DDA risk.
Medicare beneficiaries without low-income subsidies were nearly twice as likely to not fill prescriptions for serious health conditions like cancer or hepatitis C treatment, according to a new study from Vanderbilt University Medical Center researchers. The study found that 30% of patients without subsidies did not fill their prescribe...
A study in rats suggests that vitamin C supplementation can help preserve skeletal muscle after doxorubicin therapy, reducing oxidative stress and inflammation. The findings suggest vitamin C may represent a promising opportunity to reduce some of the drug's most debilitating side effects.
A recent study found that cancer treatment side effects significantly affect patients' and caregivers' eating habits, food preferences, and overall well-being. The research team identified six themes, including managing symptoms, losing taste, and caregiver burden.
A new study suggests that cardamonin, a compound from the cardamom spice, can kill triple-negative breast cancer cells and reduce PD-L1 expression. The findings hold promise for improving cancer therapy without severe side effects.
Hokkaido University scientists have identified CDK6 as a promising target for treating adult T-cell leukemia/lymphoma (ATLL) with the drug palbociclib. The combination of palbociclib with everolimus also showed significant tumor growth reduction and minimal side effects in mice models.
Researchers at CU Anschutz Medical Campus discovered a reactivated protein, Hand2, in certain cases of mesothelioma, which may lead to new treatments. The study aims to investigate the cause and effect of this reactivation.
A study led by UCL researchers found significant disparities in opioid painkiller access between countries, with some regions reporting rates as low as 0.01 MME per 1,000/day, while others have surpassed the US in opioid sales. The findings highlight the need for global policies to improve palliative care and pain relief provision.
Researchers at Okayama University have created a new method to kill cancer cells using light-activated protein AR3, reducing the risk of adverse reactions. The approach uses green light to trigger apoptosis in targeted cells, offering a promising alternative to conventional treatments.
Researchers at Penn Medicine have developed a new approach to alter immune cells for CAR T cell therapy in just 24 hours, cutting manufacturing time from nine to 14 days. This could make the therapy more cost-effective and accessible to more patients.
Researchers at Insilico Medicine have used AI to identify potential targets that are implicated in multiple age-related diseases and also play a role in the basic biology of aging. The study resulted in the identification of 69 high-confidence targets with potential high druggability.
Dr. Elaine S. Jaffe is being recognized for her pioneering work in hematopathology, including the discovery of novel pathological entities and her development of standardized diagnostic criteria for lymphoma and leukemia. She has also made significant contributions to advancing cancer research, diagnosis, treatment, and prevention.
Researchers develop innovative non-contact agitation technology to assess motility and invasive capacity of cancer cells in tissue sections. The study reveals significant increases in Rac/Cdc42 activity in tumor areas, with stronger correlations found in advanced cancer stages.
Dr. Tony Hunter's groundbreaking work on protein tyrosine phosphorylation has led to the development of targeted cancer therapies and a deeper understanding of cancer biology. His discovery has been recognized with numerous awards, solidifying his legacy in cancer research.
Researchers developed a method to identify aggressive early-stage lung cancers and target drugs to tumors likely to respond. They used genomics network models and identified signature genes associated with tumor invasiveness.
Researchers at TTUHSC will investigate common mechanisms of resistance and sensitivity in alternate telomere lengthening (ALT) cancers, with a focus on targeting ATM kinase inhibitors for therapy. The team aims to develop clinical trials for patients with ALT+ cancers.
Dr. Steven A. Rosenberg's pioneering work on IL-2 and its use in treating metastatic melanoma and other cancers led to the FDA approval of first U.S.-born cancer immunotherapy. His subsequent research on CAR T-cell therapy has resulted in promising clinical results for various types of cancer.
The FDA has approved a novel combination therapy of relatlimab and nivolumab for patients with metastatic or inoperable melanoma. The treatment significantly delayed cancer progression time compared to nivolumab alone. LAG-3 blockade reinvigorated T cell anti-tumor activity, establishing the pathway as the third immune checkpoint target.
Researchers at the University of Houston have developed a novel technology to monitor membrane protein trafficking in real-time using bioluminescence. This allows for the study of cellular processes and drug development for heart disease, metabolic disorders, cancer, infectious diseases, COVID-19, and others.
The American Association for Cancer Research (AACR) announced its newly elected class of Fellows of the AACR Academy, recognizing distinguished scientists who have propelled innovation and progress against cancer. The 2022 class consists of 33 luminaries from various scientific disciplines.
Researchers have found that immune checkpoint inhibitors like pembrolizumab can slow disease progression in patients with high-grade meningiomas. The study showed that nearly half of all patients were alive and without evidence of disease progression for at least 6 months after treatment.
Researchers found that genetic ancestry is associated with differences in biology of acute lymphoblastic leukemia (ALL) and is an independent factor contributing to treatment outcomes. Children from East Asian and South Asian backgrounds had better survival rates than Caucasian children, with Indian children having the best outcomes.
A Phase 3 clinical study of selinexor as maintenance therapy for advanced or recurrent endometrial cancer showed a 30% decrease in hazard for progression or death compared to the placebo-controlled group. Patients with functional p53 genes saw the most pronounced effect, with median progression-free survival at 10 months longer.
Researchers Miao-Ping Chien and Daan Brinks have developed a method to detect aggressive cancer cells, which can help identify the genetic profile of individual cells and develop targeted medicines. This breakthrough has the potential to improve treatment outcomes for patients with cancer.
Researchers discovered that ovarian cancer tumors evade immune attack by redirecting tryptophan breakdown to the serotonin pathway, increasing NAD+ levels. Blocking this pathway with IDO1 inhibitors can be ineffective due to the adaptation of tumor microenvironments.
The ECOG-ACRIN Cancer Research Group has opened a new treatment arm in the NCI-MATCH trial for patients with DNA mismatch repair deficiency and LAG-3 expression. The trial is evaluating two immunotherapy combinations: relatlimab plus nivolumab and dabrafenib plus trametinib, both targeting BRAF mutations.